Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects

José-Francisco Rocha, Amílcar Falcão1, Luis Almeida, Ana-Teresa Santos, Teresa Nunes, Manuel Vaz-da-Silva, Filipe Martins2, C. Fontes-Ribeiro2, Tice Macedo2, P. Soares-da-Silva

ABSTRACT

Purpose: Eslicarbazepine acetate (ESL) is a new voltage-gated sodium channel blocker currently in development for the treatment of neuropathic pain, including that of diabetic origin. The primary objective was to investigate the effect of ESL on the pharmacokinetics of metformin, a commonly used oral antidiabetic drug

2008